Skip to main content
Journal cover image

Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update.

Publication ,  Journal Article
Vamos, M; Erath, JW; Benz, AP; Lopes, RD; Hohnloser, SH
Published in: Am J Cardiol
January 1, 2019

In 2015, 3 independent meta-analyses raised concerns about digoxin therapy being associated with an increased mortality risk in patients with atrial fibrillation (AF) and with heart failure (HF). Although several other studies have been published since then fostering these safety issues, the most recent 2016 European guidelines for AF still recommend this therapy as a class I indication. We performed an updated systematic review and random-effect meta-analysis on publications up to March 2018 reporting data on digoxin associated mortality in subjects with AF or HF. Based on the adjusted survival data of all identified 37 trials comprising a total of 825,061 patients, digoxin use was associated with an increased relative risk of all-cause mortality (hazard ratio [HR] 1.17, 95% confidence interval [CI] 1.05 to 1.29, p <0.01). Treatment with digoxin was associated with an increased mortality risk in the subgroup of patients with AF (n = 627,620, HR 1.23, 95% CI, 1.17 to 1.30, p <0.01), and in the subgroup of patients with HF (n = 197,441, HR 1.11, 95% CI, 1.06 to 1.16, p<0.01). A sensitivity analysis of studies reporting data on new digoxin users (n = 41,687) demonstrated an even higher risk for all-cause mortality compared with patients not receiving cardiac glycosides (HR 1.47, 95% CI, 1.15 to 1.88, p <0.01). In conclusion, this updated meta-analysis confirms that digoxin use is associated with increased mortality in patients with AF or HF.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

January 1, 2019

Volume

123

Issue

1

Start / End Page

69 / 74

Location

United States

Related Subject Headings

  • Survival Analysis
  • Humans
  • Heart Failure
  • Digoxin
  • Cardiovascular System & Hematology
  • Atrial Fibrillation
  • Anti-Arrhythmia Agents
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vamos, M., Erath, J. W., Benz, A. P., Lopes, R. D., & Hohnloser, S. H. (2019). Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update. Am J Cardiol, 123(1), 69–74. https://doi.org/10.1016/j.amjcard.2018.09.036
Vamos, Mate, Julia Wiebke Erath, Alexander Philipp Benz, Renato Delascio Lopes, and Stefan Hans Hohnloser. “Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update.Am J Cardiol 123, no. 1 (January 1, 2019): 69–74. https://doi.org/10.1016/j.amjcard.2018.09.036.
Vamos M, Erath JW, Benz AP, Lopes RD, Hohnloser SH. Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update. Am J Cardiol. 2019 Jan 1;123(1):69–74.
Vamos, Mate, et al. “Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update.Am J Cardiol, vol. 123, no. 1, Jan. 2019, pp. 69–74. Pubmed, doi:10.1016/j.amjcard.2018.09.036.
Vamos M, Erath JW, Benz AP, Lopes RD, Hohnloser SH. Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update. Am J Cardiol. 2019 Jan 1;123(1):69–74.
Journal cover image

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

January 1, 2019

Volume

123

Issue

1

Start / End Page

69 / 74

Location

United States

Related Subject Headings

  • Survival Analysis
  • Humans
  • Heart Failure
  • Digoxin
  • Cardiovascular System & Hematology
  • Atrial Fibrillation
  • Anti-Arrhythmia Agents
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology